SEC Comment Letter 0000000000-25-002386 to NewAmsterdam Pharma Co N.V. (NAMS, NAMSW) (CIK 0001936258) (NAMS)
NewAmsterdam Pharma Co N.V. (NAMS, NAMSW) (CIK 0001936258)
Date: March 4, 2025 · CIK: 0001936258 · Accession: 0000000000-25-002386
AI Filing Summary & Sentiment
File numbers found in text: 333-285462
Letter
March 4, 2025 Michael Davidson Chief Executive Officer NewAmsterdam Pharma Co N.V. Gooimeer 2-35 1411 DC Naarden The Netherlands Re:NewAmsterdam Pharma Co N.V. Registration Statement on Form S-3 Filed February 28, 2025 File No. 333-285462 Dear Michael Davidson: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Julie M. Plyler
Show Raw Text
March 4, 2025
Michael Davidson
Chief Executive Officer
NewAmsterdam Pharma Co N.V.
Gooimeer 2-35
1411 DC Naarden
The Netherlands
Re:NewAmsterdam Pharma Co N.V.
Registration Statement on Form S-3
Filed February 28, 2025
File No. 333-285462
Dear Michael Davidson:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Julie M. Plyler